Protease inhibitor therapy for hepatitis C virus-infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M. L., Reindollar, R., Goodman, Z. D., Koury, K. J., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,027 · see citing works

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 4,525 · see citing works

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K. K., Habermann, A., Kräusslich, H., Mizokami, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1268 · Cited by 2,754 · see citing works

Replication of hepatitis C virus

Moradpour, D., Pénin, F., & Rice, C. M. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1645 · Cited by 1,337 · see citing works

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

McHutchison, J. G., Lawitz, E., Shiffman, M. L., Muir, A. J., Galler, G. W., McCone, J., Nyberg, L. M., Lee, W. M., Ghalib, R. H., Schiff, E. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808010 · Cited by 1,182 · see citing works

Epidemiology of viral hepatitis and HIV co-infection

Alter, M. J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.004 · Cited by 1,018 · see citing works

EASL Recommendations on Treatment of Hepatitis C 2016

(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 982 · see citing works

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Feld, J. J., Kowdley, K. V., Coakley, E. P. G., Sigal, S. H., Nelson, D. R., Crawford, D. H., Weiland, O., Aguilar, H. I., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 899 · see citing works

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

Poordad, F. F., Hézode, C., Trinh, R. N., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H. H., Berg, T., Yoshida, E. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402869 · Cited by 872 · see citing works

Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease

Houghton, M., Weiner, A. J., Han, J. H., Kuo, G. C., & Choo, Q. (1991) · Hepatology · doi:10.1002/hep.1840140227 · Cited by 862 · see citing works

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lawitz, E., Sulkowski, M., Ghalib, R. H., Rodriguez‐Torres, M., Younossi, Z. M., Corregidor, A., DeJesus, E., Pearlman, B. L., Rabinovitz, M., Gitlin, N., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61036-9 · Cited by 816 · see citing works

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Ferenci, P., Bernstein, D. E., Lalezari, J. P., Cohen, D. E., Luo, Y., Cooper, C., Tam, E., Marinho, R. T., Tsai, N. C. S., Nyberg, A. H., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402338 · Cited by 691 · see citing works

Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites

Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., & Rice, C. M. (1993) · Journal of Virology · doi:10.1128/jvi.67.5.2832-2843.1993 · Cited by 610 · see citing works

Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis

Veldt, B. J., Heathcote, E. J., Wedemeyer, H. H., Reichen, J., Hofmann, W. P., Zeuzem, S., Manns, M. P., Hansen, B. E., Schalm, S. W., & Janssen, H. L. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-10-200711200-00003 · Cited by 597 · see citing works

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Bourlière, M., Gordon, S. C., Flamm, S. L., Cooper, C., Ramji, A. S., Tong, M. J., Ravendhran, N., Vierling, J. M., Tran, T. T., Pianko, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613512 · Cited by 555 · see citing works

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance1 1The Bundesministerium für Bildung und Forschung and the European Union, as sponsors of the study, had no role in study design, data collection, analysis, or interpretation or in the writing and the decision to submit the report for publication.

Gerlach, J. T., Diepolder, H. M., Zachoval, R., Gruener, N. H., Jung, M., Ulsenheimer, A., Schraut, W., Schirren, C. A., Waechtler, M., Backmund, M., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00668-1 · Cited by 523 · see citing works

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

Zeuzem, S., Ghalib, R. H., Reddy, K. R., Pockros, P. J., Ben‐Ari, Z., Zhao, Y., Brown, D. D., Wan, S. M., DiNubile, M. J., Nguyen, B., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0785 · Cited by 512 · see citing works

Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶

Morgan, T. R. M., Ghany, M. G., Kim, H.-Y., Snow, K. K., Shiffman, M. L., Santo, J. L. D., Lee, W. M., Bisceglie, A. M. D., Bonkovsky, H. L., Dienstag, J. L., et al. (2010) · Hepatology · doi:10.1002/hep.23744 · Cited by 480 · see citing works

Persistence of Viremia and the Importance of Long–Term Follow–Up After Acute Hepatitis C Infection

Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., & Thomas, D. L. (1999) · Hepatology · doi:10.1002/hep.510290311 · Cited by 475 · see citing works

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E. J., Feld, J. J., Asselah, T., Bourlière, M., Ruane, P. J., Wedemeyer, H. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1702417 · Cited by 439 · see citing works

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

Sarrazin, C. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423 · see citing works

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

Gane, E. J., Lawitz, E., Pugatch, D. L., Papatheodoridis, G., Bräu, N., Brown, A. S., Pol, S., Leroy, V., Persico, M., Moreno, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704053 · Cited by 395 · see citing works

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

Kuntzen, T., Timm, J., Berical, A. C., Lennon, N. J., Berlin, A. M., Young, S., Lee, B., Heckerman, D. E., Carlson, J. M., Reyor, L. L., et al. (2008) · Hepatology · doi:10.1002/hep.22549 · Cited by 348 · see citing works

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Manns, M. P., Pol, S., Jacobson, I. M., Marcellin, P., Gordon, S. C., Peng, C., Chang, T., Everson, G. T., Heo, J., Gerken, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61059-x · Cited by 341 · see citing works

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Lawitz, E., Gane, E. J., Pearlman, B. L., Tam, E., Ghesquière, W., Guyader, D., Alric, L., Bronowicki, J., Lester, L., Sievert, W., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61795-5 · Cited by 298 · see citing works

Ultrastructural analysis of hepatitis C virus particles

Catanese, M. T., Uryu, K., Kopp, M., Edwards, T. J., Andrus, L., Rice, W. J., Silvestry, M., Kuhn, R. J., & Rice, C. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307527110 · Cited by 290 · see citing works

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Sulkowski, M., Hézode, C., Gerstoft, J., Vierling, J. M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N. M., Nahass, R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61793-1 · Cited by 280 · see citing works

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

Summa, V., Ludmerer, S. W., McCauley, J. A., Fandozzi, C. M., Burlein, C., Giuliano, C., Coleman, P. J., DiMuzio, J. M., Ferrara, M., Filippo, M. D., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-12 · Cited by 260 · see citing works

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S. Z., de Joncheere, K., & Hill, S. R. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002032 · Cited by 255 · see citing works

Expert opinion on the treatment of patients with chronic hepatitis C

Zeuzem, S., Berg, T., Moeller, B., Hinrichsen, H. M., Mauss, S., Wedemeyer, H. H., Sarrazin, C., Hueppe, D., Zehnter, E., & Manns, M. P. (2008) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.01012.x · Cited by 242 · see citing works

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Jacobson, I. M., Lawitz, E., Gane, E. J., Willems, B. E., Ruane, P. J., Nahass, R., Borgia, S. M., Shafran, S. D., Workowski, K., Pearlman, B. L., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.047 · Cited by 236 · see citing works

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu012 · Cited by 216 · see citing works

Acute hepatitis C.

Orland, J. R., Wright, T. L., & Cooper, S. (2001) · Hepatology · doi:10.1053/jhep.2001.22112 · Cited by 196 · see citing works

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

McPhee, F., Sheaffer, A. K., Friborg, J., Hernandez, D., Falk, P. J., Zhai, G., Levine, S., Chaniewski, S., Yu, F., Barry, D., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01186-12 · Cited by 189 · see citing works

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Kwo, P. Y., Gitlin, N., Nahass, R., Bernstein, D. E., Etzkorn, K., Rojter, S. E., Schiff, E. R., Davis, M. N., Ruane, P. J., Younes, Z. H., et al. (2016) · Hepatology · doi:10.1002/hep.28467 · Cited by 188 · see citing works

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Bersoff‐Matcha, S. J., Cao, K., Jason, M., Ajao, A. O., Jones, S. C., Meyer, T. E., & Brinker, A. D. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0377 · Cited by 187 · see citing works

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Lawitz, E., Matusow, G., DeJesus, E., Yoshida, E. M., Felizarta, F., Ghalib, R. H., Godofsky, E. W., Herring, R. W., Poleynard, G. D., Sheikh, A. M., et al. (2015) · Hepatology · doi:10.1002/hep.28422 · Cited by 180 · see citing works

Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis

Chen, G., Wang, C., Chen, J., Ji, D., Wang, Y., Wu, V., KARLBERG, J. P. E., & Lau, G. K. K. (2017) · Hepatology · doi:10.1002/hep.29109 · Cited by 163 · see citing works

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks

Feld, J. J., Moreno, C., Trinh, R. N., Tam, E., Bourgeois, S., Horsmans, Y., Elkhashab, M., Bernstein, D. E., Younes, Z. H., Reindollar, R., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.005 · Cited by 160 · see citing works

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

Reesink, H. W., Fanning, G. C., Farha, K. A., Weegink, C. J., van Vliet, A., Klooster, G. A. E. V. '., Lenz, O., Aharchi, F., Mariën, K., Remoortere, P. V., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.033 · Cited by 155 · see citing works

Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment

Bartels, D. J., Sullivan, J. C., Zhang, E. Z., Tigges, A. M., Dorrian, J., Meyer, S. D., Takemoto, D., Dondero, E., Kwong, A. D., Picchio, G., et al. (2012) · Journal of Virology · doi:10.1128/jvi.02294-12 · Cited by 147 · see citing works

Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy #

Gaudieri, S., Rauch, A., Pfafferott, K. J., Barnes, E. J., Cheng, W., McCaughan, G. W., Shackel, N. A., Jeffrey, G. P., Mollison, L. C., Baker, R. I., et al. (2008) · Hepatology · doi:10.1002/hep.22773 · Cited by 140 · see citing works

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

Forns, X., Gordon, S. C., Zuckerman, E., Lawitz, E., Calleja, J. L., Hofer, H., Gilbert, C., Palcza, J. S., Howe, A., DiNubile, M. J., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.009 · Cited by 138 · see citing works

Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals

Belperio, P. S., Shahoumian, T. A., Mole, L. A., & Backus, L. I. (2017) · Hepatology · doi:10.1002/hep.29135 · Cited by 135 · see citing works

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

Lenz, O., Verbinnen, T., Fevery, B., Tambuyzer, L., Vijgen, L., Peeters, M., Buelens, A., Ceulemans, H., Beumont, M. G., Picchio, G., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.032 · Cited by 132 · see citing works

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

Hézode, C., Hirschfield, G. M., Ghesquière, W., Sievert, W., Rodriguez‐Torres, M., Shafran, S. D., Thuluvath, P. J., Tatum, H. A., Waked, I. A., Esmat, G., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-307498 · Cited by 120 · see citing works

Hepatitis C virus NS3/4a protease inhibitors

McCauley, J. A., & Rudd, M. T. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.015 · Cited by 120 · see citing works

In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450

Pilot-Matias, T., Tripathi, R. L., Cohen, D. E., Gaultier, I., Dekhtyar, T., Lu, L., Reisch, T., Irvin, M., Hopkins, T., Pithawalla, R. B., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04227-14 · Cited by 117 · see citing works

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV

Liu, C., Chuang, W., Sheen, I., Wang, H., Chen, C.-Y., Tseng, K., Chang, T., Massetto, B., Yang, J. C., Yun, C., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.11.011 · Cited by 117 · see citing works

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study

Moreno, C., Berg, T., Tanwandee, T., Thongsawat, S., Vlierberghe, H. V., Zeuzem, S., Lenz, O., Peeters, M., Sekar, V. J., & Smedt, G. D. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.033 · Cited by 109 · see citing works

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Gane, E. J., Poordad, F. F., Wang, S., Asatryan, A., Kwo, P. Y., Lalezari, J. P., Wyles, D. L., Hassanein, T., Aguilar, H. I., Maliakkal, B. J., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.020 · Cited by 103 · see citing works

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

Sarrazin, C., Lathouwers, E., Peeters, M., Daems, B., Buelens, A., Witek, J., Wyckmans, Y., Fevery, B., Verbinnen, T., Ghys, A., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.003 · Cited by 102 · see citing works

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir

Krishnan, P., Tripathi, R. L., Schnell, G., Reisch, T., Beyer, J. M., Irvin, M., Xie, W., Larsen, L. M., Cohen, D. E., Podsadecki, T. J., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-15 · Cited by 96 · see citing works

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.

Buti, M., Gordon, S. C., Zuckerman, E., Lawitz, E., Calleja, J. L., Hofer, H., Gilbert, C., Palcza, J. S., Howe, A. Y. M., DiNubile, M. J., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ722 · Cited by 91 · see citing works

Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202)

Lenz, O., Vijgen, L., Berke, J. M., Cummings, M. D., Fevery, B., Peeters, M., Smedt, G. D., Moreno, C., & Picchio, G. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.028 · Cited by 87 · see citing works

O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens

Krishnan, P., Tripathi, R. L., Schnell, G., Reisch, T., Beyer, J. M., Dekhtyar, T., Irvin, M., Xie, W., Larsen, L. M., Podsadecki, T. J., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30071-4 · Cited by 83 · see citing works

The Burden of Liver Disease in Human Immunodeficiency Virus-Infected Patients

Puoti, M., Moioli, M. C., Travi, G., & Rossotti, R. (2012) · Seminars in Liver Disease · doi:10.1055/s-0032-1316473 · Cited by 82 · see citing works

Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial

Rockstroh, J. K., Bhagani, S. R., Hyland, R. H., Yun, C., Dvory‐Sobol, H., Zheng, W., Brainard, D. M., Ingiliz, P., Lutz, T., Boesecke, C., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30003-1 · Cited by 79 · see citing works

Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors

Bae, A. S., Sun, S.-C. C., Qi, X., Chen, X., Ku, K. S., Worth, A., Wong, K. A., Harris, J. L., Miller, M. D., & Mo, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00777-10 · Cited by 76 · see citing works

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients

Dietz, J., Süsser, S., Berkowski, C., Perner, D., Zeuzem, S., & Sarrazin, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134395 · Cited by 74 · see citing works

GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study

Rodriguez‐Torres, M., Glass, S., Hill, J., Freilich, B. L., Hassman, D. R., Bisceglie, A. M. D., Taylor, J. G., Kirby, B. J., Dvory‐Sobol, H., Yang, J. C., et al. (2016) · Journal of Viral Hepatitis · doi:10.1111/jvh.12527 · Cited by 65 · see citing works

Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a

Palanisamy, N., Danielsson, A., Kokkula, C., Yin, H., Bondeson, K., Wesslén, L., Duberg, A., & Lennerstrand, J. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.04.018 · Cited by 64 · see citing works

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease

Soumana, D. I., Yılmaz, N. K., Ali, A., Prachanronarong, K., & Schiffer, C. A. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06454 · Cited by 62 · see citing works

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

Lawitz, E., O’Riordan, W. D., Asatryan, A., Freilich, B. L., Box, T. D., Overcash, J. S., Lovell, S., Ng, T. I., Liu, W., Campbell, A. L., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02264-15 · Cited by 61 · see citing works

Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection

Dore, G. J., Lawitz, E., Hézode, C., Shafran, S. D., Ramji, A. S., Tatum, H. A., Taliani, G., Tran, A., Brunetto, M. R., Zaltron, S., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.007 · Cited by 58 · see citing works

NS3 Protease Polymorphism and Natural Resistance to Protease Inhibitors in French Patients Infected with HCV Genotypes 1–5

the ANRS AC11 HCV Group, Vallet, S., Viron, F., Henquell, C., Guillou‐Guillemette, H. L., Lagathu, G., Abravanel, F., Trimoulet, P., Soussan, P., Schvoerer, É., et al. (2011) · Antiviral Therapy · doi:10.3851/imp1900 · Cited by 55 · see citing works

Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C

Pasquinelli, C., McPhee, F., Eley, T., Villegas, C., Sandy, K., Sheridan, P. L., Persson, A., Huang, S.-P., Hernandez, D., Sheaffer, A. K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05854-11 · Cited by 51 · see citing works

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial

Welzel, T. M., Asselah, T., Dumas, E. O., Zeuzem, S., Shaw, D., Hazzan, R., Forns, X., Pilot-Matias, T., Lu, W., Cohen, D. E., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30071-7 · Cited by 48 · see citing works

Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?

Arends, J. E., Lieveld, F. I., Boeijen, L. L., de Kanter, C. T. M. M., van Erpecum, K. J., Salmon, D., Hoepelman, A. I. M., Asselah, T., & Ustianowski, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.034 · Cited by 47 · see citing works

Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral ( DAA )‐based hepatitis C virus ( HCV ) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?

Bischoff, J., Mauss, S., Cordes, C., Lutz, T., Scholten, S., Moll, A., Jäger, H., Cornberg, M., Manns, M., Baumgarten, A., et al. (2018) · HIV Medicine · doi:10.1111/hiv.12579 · Cited by 44 · see citing works

P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial

Kwo, P. Y., Gane, E. J., Peng, C., Pearlman, B. L., Vireling, J., Serfaty, L., Buti, M., Shafran, S. D., Stryszak, P., Lin, L.-W., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)31088-6 · Cited by 39 · see citing works

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

Howe, A., Black, S., Curry, S., Ludmerer, S. W., Liu, R., Barnard, R. J. O., Newhard, W., Hwang, P. M. T., Nickle, D. C., Gilbert, C., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu696 · Cited by 36 · see citing works

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

Coilly, A., Dumortier, J., Botta‐Fridlund, D., Latournerie, M., Leroy, V., Pageaux, G., Agostini, H., Giostra, E., Moreno, C., Roche, B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138091 · Cited by 35 · see citing works

Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment

Cohn, J., Roberts, T., Amorosa, V., Lemoine, M., & Hill, A. M. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000180 · Cited by 35 · see citing works

HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

Neukam, K., Morano, L. E., Rivero‐Juárez, A., Mancebo, M., Granados, R., Téllez, F., Collado, A., Ríos, M. J., Santos, I. D. L., Reus, S., et al. (2017) · HIV Clinical Trials · doi:10.1080/15284336.2017.1330801 · Cited by 34 · see citing works

P0899 : Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857

Taylor, J. G., Appleby, T. C., Barauskas, O., Chen, X., Dvory‐Sobol, H., Gong, R., Lee, J., Nejati, E., Schultz, B. E., Wang, Y., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)31102-8 · Cited by 31 · see citing works

Hepatitis C genotype 3 disease

Kattakuzhy, S. M., Levy, R., Rosenthal, E. S., Tang, L., Wilson, E. M. P., & Kottilil, S. (2016) · Hepatology International · doi:10.1007/s12072-016-9748-z · Cited by 30 · see citing works

Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor

Lawitz, E., Yang, J. C., Stamm, L. M., Taylor, J. G., Cheng, G., Brainard, D. M., Miller, M. D., Mo, H., & Dvory‐Sobol, H. (2017) · Antiviral Therapy · doi:10.3851/imp3202 · Cited by 25 · see citing works

Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure

Wyles, D. L., Wedemeyer, H. H., Ben‐Ari, Z., Gane, E. J., Hansen, J. B., Jacobson, I. M., Laursen, A. L., Luetkemeyer, A. F., Nahass, R., Pianko, S., et al. (2017) · Hepatology · doi:10.1002/hep.29358 · Cited by 25 · see citing works

Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes

Meyer, S. D., Ghys, A., Foster, G. R., Beumont, M. G., van Baelen, B., Lin, T. I., Dierynck, I., Ceulemans, H., & Picchio, G. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12046 · Cited by 19 · see citing works

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin

Howe, J. A., Long, J., Black, S., Chase, R., McMonagle, P., Curry, S., Thompson, S., DiNubile, M. J., & Howe, A. Y. M. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu078 · Cited by 18 · see citing works

G07 : The phase 3 C-EDGE treatment-naïve (TN) study of a 12-week oral regimen of grazoprevir (GZR, MK-5172)/ elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection

Zeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ben‐Ari, Z., Zhao, Y., Brown, D. C., DiNubile, M. J., Robertson, M. N., Wahl, J., et al. (2015) · Journal of Hepatology · doi:10.1016/s0168-8278(15)30056-8 · Cited by 15 · see citing works

Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study

Deterding, K., Spinner, C. D., Schott, E., Welzel, T. M., Gerken, G., Klinker, H., Spengler, U., Wiegand, J., Wiesch, J. S. Z., Pathil, A., et al. (2016) · Journal of Hepatology · doi:10.1016/s0168-8278(16)00177-x · Cited by 13 · see citing works

MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure

Poordad, F. F., Pol, S., Asatryan, A., Buti, M., Shaw, D., Hézode, C., Lalezari, J. P., Felizarta, F., Reindollar, R., Gordon, S. C., et al. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)33570-9 · Cited by 12 · see citing works

High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (AGATE-I)

Asselah, T., Hézode, C., Qaqish, R. B., Elkhashab, M., Hassanein, T., Papatheodoridis, G., Feld, J. J., Alqahtani, S. A., Pilot-Matias, T., Yu, Y., et al. (2016) · Journal of Hepatology · doi:10.1016/s0168-8278(16)01618-4 · Cited by 11 · see citing works

Grazoprevir/elbasvir fixed-dose combination for hepatitis C

Gamal, N., & Andreoné, P. (2016) · Drugs of today · doi:10.1358/dot.2016.52.7.2510258 · Cited by 6 · see citing works

Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530

Ng, T., Pilot-Matias, T., Tripathi, R. L., Schnell, G., Reisch, T., Beyer, J. M., Dekhtyar, T., Wang, S., Mensa, F., Kort, J., et al. (2016) · Journal of Hepatology · doi:10.1016/s0168-8278(16)00653-x · Cited by 6 · see citing works

Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256

Mo, H., Hedskog, C., Lawitz, E., Brainard, D. M., Yang, J. C., Delaney, W. E., Worth, A., & Miller, M. D. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.01.015 · Cited by 5 · see citing works

Advances in covalent drug discovery

Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823 · see citing works

Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds

Fischer, A., Sellner, M. S., Neranjan, S., Lill, M. A., & Smieško, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103626 · Cited by 165 · see citing works

Development of nanoparticle-delivery systems for antiviral agents: A review

Delshadi, R., Bahrami, A., McClements, D. J., Moore, M. D., & Williams, L. L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.017 · Cited by 126 · see citing works

Drugs for the Treatment of Zika Virus Infection

Bernatchez, J. A., Tran, L., Li, J., Luan, Y., Siqueira-Neto, J. L., & Li, R. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00775 · Cited by 109 · see citing works

More than just oncogenes: mechanisms of tumorigenesis by human viruses

Gaglia, M. M., & Münger, K. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.09.003 · Cited by 105 · see citing works

Multi-input chemical control of protein dimerization for programming graded cellular responses

Wink, G., Wang, Z., Wei, C. T., Greisen, P. J., Warner, K., Cunningham‐Bryant, D., Park, K., Brunette, T., Sheffler, W., Baker, D. A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0242-8 · Cited by 77 · see citing works

Inhibitors of the Zika virus protease NS2B-NS3

Voss, S., & Nitsche, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.126965 · Cited by 78 · see citing works

Synthetic Approaches to the New Drugs Approved During 2017

Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Helal, C. J., & O’Donnell, C. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00196 · Cited by 72 · see citing works

Molecular design opportunities presented by solvent‐exposed regions of target proteins

Jiang, X., Yu, J. H., Zhou, Z., Kongsted, J., Song, Y., Pannecouque, C. C., Clercq, E. D., Kang, D., Poongavanam, V., Liu, X., et al. (2019) · Medicinal Research Reviews · doi:10.1002/med.21581 · Cited by 57 · see citing works

Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease

Al-Karmalawy, A. A., Alnajjar, R. A., Dahab, M. A., Metwaly, A. M., & Eissa, I. H. (2021) · Pharmaceutical Sciences · doi:10.34172/ps.2021.3 · Cited by 53 · see citing works

Design, synthesis, molecular docking and DFT computational insight on the structure of Piperazine sulfynol derivatives as a new antibacterial contender against superbugs MRSA

Prasad, H. S. N., Ananda, A. P., Lohith, T. N., Prabhuprasad, P., Jayanth, H. S., Krishnamurthy, N. B., Sridhar, M. A., Mallesha, L., & Mallu, P. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131333 · Cited by 54 · see citing works

In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases

Tasdemiroglu, Y., Gourdie, R. G., & He, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175192 · Cited by 49 · see citing works

The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19

Bege, M., & Borbás, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020217 · Cited by 48 · see citing works

Enzymatic Formation of Oxygen‐Containing Heterocycles in Natural Product Biosynthesis

Meng, S., Tang, G., & Pan, H. (2018) · ChemBioChem · doi:10.1002/cbic.201800225 · Cited by 40 · see citing works

Hepatitis C Virus: 30 Years after Its DiscoveryPreprint

Houghton, M. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037069 · Cited by 38 · see citing works

Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million CompoundsPreprint

Fischer, A., Sellner, M. S., Neranjan, S., Lill, M. A., & Smieško, M. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11923239 · Cited by 38 · see citing works

Design, Synthesis, and Characterization of Macrocyclic Inhibitors of the Proprotein Convertase Furin

van, T. V. L., Ivanova, T., Hardes, K., Heindl, M. R., Morty, R. E., Böttcher‐Friebertshäuser, E., Lindberg, I., Than, M. E., Dahms, S. O., & Steinmetzer, T. (2019) · ChemMedChem · doi:10.1002/cmdc.201800807 · Cited by 37 · see citing works

Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation

Kammarabutr, J., Mahalapbutr, P., Nutho, B., Kungwan, N., & Rungrotmongkol, T. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.03.006 · Cited by 30 · see citing works

More than efficacy revealed by single-cell analysis of antiviral therapeutics

Liu, W., Caglar, M. U., Mao, Z., Woodman, A., Arnold, J. J., Wilke, C. O., & Cameron, C. E. (2019) · Science Advances · doi:10.1126/sciadv.aax4761 · Cited by 23 · see citing works

Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors

Akaberi, D., Båhlström, A., Chinthakindi, P. K., Nyman, T., Sandström, A., Järhult, J. D., Palanisamy, N., Lundkvist, Å., & Lennerstrand, J. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105074 · Cited by 22 · see citing works

Viral resistance in HCV infection

Ceccherini‐Silberstein, F., Cento, V., Maio, V. C. D., Perno, C. F., & Craxı̀, A. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.10.005 · Cited by 22 · see citing works

Allosteric Inhibitors of Zika Virus NS2B-NS3 Protease Targeting Protease in “Super-Open” Conformation

Meewan, I., Shiryaev, S. A., Kattoula, J. Y., Huang, C., Lin, Y.-W., Chuang, C.-H., Terskikh, A. V., & Abagyan, R. A. (2023) · Viruses · doi:10.3390/v15051106 · Cited by 20 · see citing works

Current Advances in Japanese Encephalitis Virus Drug Development

Guo, J., Mi, Y., Guo, Y. Q., Bai, Y., Wang, M., Wang, W., & Wang, Y. (2024) · Viruses · doi:10.3390/v16020202 · Cited by 15 · see citing works

Targeting the protease of West Nile virus

Voss, S., & Nitsche, C. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00080b · Cited by 14 · see citing works

Modular Peroxidase-Based Reporters for Detecting Protease Activity and Protein Interactions with Temporal Gating

Zhou, G., Wan, W. W., & Wang, W. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08280 · Cited by 15 · see citing works

Novel inhibitors of HSV-1 protease effective in vitro and in vivo

Pachota, M., Grzywa, R., Iwanejko, J., Synowiec, A., Iwan, D., Kamińska, K., Skoreński, M., Bielecka, E., Szczubiałka, K., Nowakowska, M., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105604 · Cited by 13 · see citing works

Towards curative therapy of chronic viral hepatitis

Bartenschlager, R. F. W., Urban, S., & Protzer, U. (2019) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0824-1576 · Cited by 13 · see citing works

Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease

Akaberi, D., Chinthakindi, P. K., Båhlström, A., Palanisamy, N., Sandström, A., Lundkvist, Å., & Lennerstrand, J. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1704882 · Cited by 15 · see citing works

Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients

Aldunate, F., Echeverría, N., Chiodi, D., López, P. L., Sánchez-Cicerón, A., Fajardo, Á., Sóñora, M., Cristina, J., Hernández, N., & Moreno, P. (2018) · Disease Markers · doi:10.1155/2018/2514901 · Cited by 12 · see citing works

Taming a beast: lessons from the domestication of hepatitis C virus

Luna, J. M., Saeed, M., & Rice, C. M. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.02.008 · Cited by 12 · see citing works

De novo Design of SARS-CoV-2 Main Protease Inhibitors

Vepřek, N. A., Peitsinis, Z. V., Zhang, Y., Trauner, D. H., Fischer, C., Ruehmann, K.-P., Yang, C., Spradlin, J. N., Dovala, D., & Nomura, D. K. (2021) · Synlett · doi:10.1055/a-1582-0243 · Cited by 12 · see citing works

Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data

Qin, W., Zhao, B., Shang, Y., & Zhang, L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1933942 · Cited by 10 · see citing works

The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection

Alqahtani, S. A., & Sulkowski, M. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2018_59 · Cited by 9 · see citing works

Antiviral Peptides Delivered by Chitosan-Based Nanoparticles to Neutralize SARS-CoV-2 and HCoV-OC43

Mali, A., Franci, G., Zannella, C., Chianese, A., Anthiya, S., López-Estévez, A. M., Monti, A., Filippis, A. D., Doti, N., Alonso, M. J., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061621 · Cited by 8 · see citing works

Extraction of protein with protease inhibitor activity from Brazilwood (Caesalpinia echinata LAM.) seeds using choline-based ionic liquids

Feitosa, I. M. D., Pinto, R. E. P., Pereira, M. M., Soares, C. M. F., & Lima, Á. S. (2023) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2022.100956 · Cited by 7 · see citing works

Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?

Koutsoumpli, G., Ip, P. P., Schepel, I., Hoogeboom, B. N., Boerma, A., & Daemen, T. (2019) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135519874677 · Cited by 7 · see citing works

Resistance mutations of NS3 and NS5b in treatment-naïve patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil

de Andrade, E. F., Rocha, D., Fontana‐Maurell, M., Costa, E. M., Ribeiro, M., de Godoy, D. T., Ferreira, A., Tanuri, A., Brindeiro, R., & Álvarez, P. (2019) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2018-0237 · Cited by 6 · see citing works

Unraveling the anti-dengue viral potential of protease inhibitors from Streptomyces spp.

Kumari, A., & Rao, K. V. B. (2025) · Chemistry Africa · doi:10.1007/s42250-025-01275-3 · Cited by 5 · see citing works

Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity

Kawall, A., Lewis, D. S. M., Sharma, A., Chavada, K., Deshmukh, R. R., Rayalam, S., Mody, V. V., & Taval, S. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2022.1100460 · Cited by 5 · see citing works

Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure–Activity Relationships

Hu, K., Zhu, Z., Mathahs, M. M., Tran, H. T. T., Bommer, J. C., Testa, C. A., & Schmidt, W. N. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s201089 · Cited by 4 · see citing works

Drug Discovery Beyond the Rule of Five

DeGoey, D. A., & Cox, P. B. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc258 · Cited by 3 · see citing works

Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran

Cuypers, L., Thijssen, M., Shakibzadeh, A., Deboutte, W., Sarvari, J., Sabahi, F., Ravanshad, M., & Pourkarim, M. R. (2019) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2019.103966 · Cited by 2 · see citing works

Antiviral İlaçlar

Küçük, A., & YILDIRIM, Y. (2019) · Etlik Veteriner Mikrobiyoloji Dergisi · doi:10.35864/evmd.586573 · Cited by 2 · see citing works

The serine peptidase inhibitor N-ρ-tosyl-l-phenylalanine chloromethyl ketone (TPCK) affects the cell biology of Candida haemulonii species complex

Souto, X. M., Ramos, L. S., Oliveira, S. S. C., Branquinha, M. H., & dos Santos, A. L. S. (2020) · Fungal Biology · doi:10.1016/j.funbio.2020.12.004 · Cited by 2 · see citing works

Nucleoside Antiviral Agents for HCV

Amblard, F., Mengshetti, S., Shi, J., Tao, S., Bassit, L., & Schinazi, R. F. (2020) · doi:10.1002/9781119436812.ch67 · Cited by 1 · see citing works

CD4+ T Lymphocytes Are the Only HIV-1 Reservoir in Individuals Receiving Combination Antiretroviral Therapy…or Not?

Salhi, A. (2018) · Advances in Biotechnology & Microbiology · doi:10.19080/aibm.2018.10.555789

Avaliação de marcadores histológicos e imuno-histoquímicos em amostras hepáticas de pacientes soropositivos para hepatite C com ênfase aos padrões de vasos sanguíneos e linfáticos

Assato, A. K. (2021) · doi:10.11606/d.5.2021.tde-10032022-095437

Application of the Synthetic Escherichia coli’s Twin-Arginine Translocation Pathway for the Detection of Intracellular Antibodies against Hepatitis C Viral Protease

Kamthong, A., Boonyalekha, P., Leelawattanachai, J., & Waraho‐Zhmayev, D. (2019) · International Journal of Bioscience Biochemistry and Bioinformatics · doi:10.17706/ijbbb.2020.10.1.49-57

Drug resistance mechanism of ns3/4a protease and identification of potent compounds inhibiting reverse transcriptase of hepatitis virus

Kammarabutr, J. (2018) · doi:10.58837/chula.the.2018.7

Carbazole Tethered Triazoles as Potential NS5A/NS5B Inhibitors: Synthesis, Molecular Docking, MD Simulation, ADMET and DFT Studies

Munawar, S., & Zahoor, A. F. (2026) · ChemistrySelect · doi:10.1002/slct.202506286

Asymmetric Synthesis of Oxaproline-Based Tripeptides Analogs of Asunaprevir and their Biological Evaluations

Hamdi, A. (2020) · doi:10.70675/9be53a46z5efdz4860z9fc7z2eaf6a520097

BindingDB Entry 50004309: Targeting the protease of West Nile virus.

BindingDB (2024) · UC San Diego · doi:10.7270/q27948vx

BindingDB Entry 50007918: Drugs for the Treatment of Zika Virus Infection.

BindingDB (2021) · UC San Diego · doi:10.7270/q2rx9gfs

BindingDB Entry 50007904: Synthetic Approaches to the New Drugs Approved During 2017.

BindingDB (2021) · UC San Diego · doi:10.7270/q2sx6hk5

BindingDB Entry 50010800: Inhibitors of the Zika virus protease NS2B-NS3.

BindingDB (2021) · UC San Diego · doi:10.7270/q27m0cgt

Protease inhibitors for the treatment of hepatitis C virus infection

de Leuw, P., & Stephan, C. (2017) · Europe PMC (PubMed Central) · doi:10.3205/id000034 · Cited by 51 · see citing works

Treatment of chronic hepatitis C in patients with HIV/HCV coinfection

Coppola, N. (2015) · World Journal of Virology · doi:10.5501/wjv.v4.i1.1 · Cited by 26 · see citing works

New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets

Ploß, A., & Dubuisson, J. (2012) · Gut · doi:10.1136/gutjnl-2012-302048 · Cited by 85 · see citing works

Direct-Acting Antiviral Drugs for Treatment of Hepatitis C Virus Infection-Clinical Trials Data and Chemistry of NS3/4a Protease Inhibitors

Senćanski, M., & Glišić, S. (2020) · Frontiers in clinical drug research. Anti-infectives/Frontiers in clinical drug research. Anti infectives · doi:10.2174/9789811425745120060001 · Cited by 1 · see citing works

Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors

Naggie, S., Patel, K., & McHutchison, J. G. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq284 · Cited by 40 · see citing works